Sight Sciences 경영진
경영진 기준 점검 3/4
Sight Sciences CEO는 Paul Badawi, Jan2011 에 임명되었습니다 의 임기는 15.67 년입니다. 총 연간 보상은 $2.01M, 32.9% 급여 및 67.1% 보너스(회사 주식 및 옵션 포함)로 구성됩니다. 는 $45.36M 가치에 해당하는 회사 주식의 10.12% 직접 소유합니다. 경영진과 이사회의 평균 재임 기간은 0.8 년과 6.2 년입니다.
핵심 정보
Paul Badawi
최고경영자
US$2.0m
총 보수
| CEO 급여 비율 | 32.86% |
| CEO 재임 기간 | 15.7yrs |
| CEO 지분 보유율 | 10.1% |
| 경영진 평균 재임 기간 | less than a year |
| 이사회 평균 재임 기간 | 6.2yrs |
최근 경영진 업데이트
Recent updates
내러티브 업데이트 • Aug 18
SGHT: Medtech Procedure Trends And Glaucoma Platform Execution Will Guide Measured Repricing
Analysts have raised their price target on Sight Sciences to $8 from $6, citing more constructive views on medical technology procedure volumes and what they view as more reasonable estimates for 2026 and 2027. Analyst Commentary Recent research on Sight Sciences points to a mixed backdrop, with several firms lifting price targets while still highlighting risks around procedure trends, growth expectations and valuation.
내러티브 업데이트 • Aug 04
SGHT: Strong Eyecare Demand And Dry Eye Coverage Will Support Upside
The fair value estimate for Sight Sciences has been adjusted to $8.40 from $9.35 as analysts revise their models in response to lower Street price targets and updated expectations for growth, profitability, and future P/E multiples. Analyst Commentary Recent Street research on Sight Sciences reflects a mix of renewed interest and caution, with several experts revisiting targets and ratings as they update models for the eyecare and broader medical technology space.내러티브 업데이트 • Jul 15
SGHT: Medtech Sector Support And Dry Eye Expansion Will Drive Measured Repricing
Analysts have adjusted their stance on Sight Sciences by moving the price target to $6.00 from $5.15, citing updated medtech sector models and a preference for higher-quality stocks during what they describe as a skittish trading backdrop. Analyst Commentary on Sight Sciences Recent commentary on Sight Sciences reflects a mixed tone.내러티브 업데이트 • Jul 01
SGHT: Sector Strength And Dry Eye Outlook Will Support Measured Repricing
Analysts lifted their price target on Sight Sciences to $5.15 from $4.35, citing updated medical technology sector models after Q1 reports and a view that sector fundamentals remain solid. Analyst Commentary Recent commentary on Sight Sciences reflects a mixed stance, with some analysts adjusting their models after the latest Q1 updates while keeping a neutral overall view on the stock.
내러티브 업데이트 • Jun 17
SGHT: Sector Support And Dry Eye Execution Will Drive Future Upside
Analysts have increased their price target on Sight Sciences stock to $5.15 from $4.35, citing refreshed medical technology sector models after Q1 updates and a view that broader fundamentals in the space remain solid. Analyst Commentary on Sight Sciences Recent research commentary on Sight Sciences centers on refreshed models following Q1 updates and a reassessment of where the stock fits within the broader medical technology group.내러티브 업데이트 • Jun 02
SGHT: Dry Eye Execution And TearCare Adoption Will Support Future Upside
Analysts have maintained Sight Sciences' fair value target at $12.00 while refining underlying assumptions such as discount rate and margin forecasts. Recent Street research highlights sector models being refreshed and mixed segment trends as key drivers of the updated $5.15 Citi price target and other revised targets across the stock.내러티브 업데이트 • May 10
SGHT: Weaker Glaucoma Trends Will Limit Rerating Despite Solid Dry Eye Momentum
Analysts have trimmed their price targets for Sight Sciences, with one key target moving from $6.50 to $5 and another from $12 to $11. These revisions reflect updated views on a mix of steady sector fundamentals, solid Dry Eye performance, and softer Surgical Glaucoma trends.내러티브 업데이트 • Apr 23
SGHT: Dry Eye Franchise And TearCare Adoption Will Drive Future Upside
The blended analyst price target for Sight Sciences has moved modestly lower to $11 from $12, as analysts balance pressure in Surgical Glaucoma against steady TearCare adoption, sector wide target resets, and updated assumptions for the discount rate, revenue growth, profit margin, and future P/E. Analyst Commentary Recent research updates show a wide range of views on Sight Sciences, with price targets clustered between the mid single digits and low double digits and ratings spanning Neutral to Buy.내러티브 업데이트 • Apr 08
SGHT: TearCare And Dry Eye Adoption Will Support Future Upside Potential
Narrative Update on Sight Sciences Analysts have adjusted price targets for Sight Sciences into a range of $5 to $11, reflecting updated views on the balance between softer Surgical Glaucoma trends and stronger TearCare and Dry Eye performance. Overall sector fundamentals are described as healthy.내러티브 업데이트 • Mar 25
SGHT: Dry Eye Momentum Will Support Stronger Outlook Than Surgical Glaucoma
Analysts have trimmed their average price target on Sight Sciences by $1.00, reflecting updated assumptions around growth, margins and sector risk after recent research highlighted mixed trends between TearCare strength and softer Surgical Glaucoma performance. Analyst Commentary Street research on Sight Sciences has converged around a more cautious but still constructive stance, with price targets adjusted to reflect mixed trends between TearCare strength and softer Surgical Glaucoma performance.내러티브 업데이트 • Mar 11
SGHT: TearCare Momentum Will Support Rerating Despite Surgical Glaucoma Concerns
The updated analyst price target for Sight Sciences moves to $6.50, reflecting a blended view where some analysts trimmed targets, others raised them toward $8 to $11, and recent feedback on TearCare and mixed segment trends shaped modest adjustments to fair value, discount rate, revenue growth, profit margin, and future P/E assumptions. Analyst Commentary Recent research on Sight Sciences gives you a mixed picture, with some analysts more constructive on TearCare adoption and others turning more cautious on execution and growth in the surgical glaucoma segment.내러티브 업데이트 • Feb 24
SGHT: Longer Term Glaucoma Data Will Support Stronger Outlook For Therapy
Analysts have maintained their $12.00 price target on Sight Sciences, noting that minor adjustments to the discount rate, revenue growth, profit margin, and future P/E assumptions largely offset one another. What's in the News Sight Sciences issued new earnings guidance for the fourth quarter of 2025, with total revenue expected between $20.3 million and $20.4 million, described as a 7% increase at the midpoint compared to the prior year period (Key Developments).내러티브 업데이트 • Feb 09
SGHT: Longer Term Glaucoma Data Will Support Stronger Outlook For Therapy
Analysts have kept their price target for Sight Sciences steady at US$12.00, citing updated assumptions that include slightly higher discount and P/E expectations, along with adjusted revenue growth and profit margin forecasts. What's in the News Sight Sciences issued earnings guidance for the fourth quarter of 2025, with total revenue projected between US$20.3 million and US$20.4 million.내러티브 업데이트 • Jan 26
SGHT: Fair Outlook Balances Guidance Revision With Leadership And Margin Assumptions
Analysts have lifted their price target for Sight Sciences from US$3.60 to US$6.00, pointing to updated assumptions around revenue growth, profit margins, discount rate and a higher future P/E multiple as key drivers of the change. What's in the News Sight Sciences issued earnings guidance for the fourth quarter of 2025, with total revenue expected between US$20.3 million and US$20.4 million, described as a 7% increase at the midpoint compared to the prior year period (Corporate Guidance).분석 기사 • Jan 21
Sight Sciences, Inc.'s (NASDAQ:SGHT) 26% Share Price Plunge Could Signal Some Risk
The Sight Sciences, Inc. ( NASDAQ:SGHT ) share price has softened a substantial 26% over the previous 30 days, handing...내러티브 업데이트 • Jan 11
SGHT: Final Medicare Coverage Will Support Dry Eye Upside Potential
Analysts have lifted their price target on Sight Sciences from $7.85 to $9.35, citing recent Medicare coverage decisions for the TearCare dry eye disease treatment system as a key support for their updated view. Analyst Commentary Bullish Takeaways Bullish analysts view the finalized Medicare coverage policies for TearCare as a key support for the higher price targets, since clearer reimbursement can make revenue visibility easier to model.Seeking Alpha • Dec 31
Sight Sciences: Improving Medicare Coverage Drives Eye-Popping Price Surge
Summary Sight Sciences surged over 100% after two major Medicare contractors approved coverage for its TearCare dry eye treatment. Positive reimbursement decisions for TearCare open up a sizable market opportunity ($400 ASP and multiple millions of treatable patients) that was severely limited on a self-pay basis. OMNI is still the much larger business today, and while the company secured a positive reimbursement decision, market penetration may be limited or slowed by the company's tight finances. SGHT faces significant liquidity risks, and I believe the company should look to raise cash in 2026, particularly in light of the recent share price surge. I see fair value near $9.50/share, but further upside depends on sales execution and additional coverage wins. Read the full article on Seeking Alpha내러티브 업데이트 • Dec 26
SGHT: Medicare Coverage Expansion Will Drive Stronger Outlook For Dry Eye Therapy
Analysts have raised their price target on Sight Sciences from $5 to $7 per share, citing recently finalized Medicare coverage policies for the TearCare dry eye treatment system as a key potential driver of outperformance. Analyst Commentary Bullish analysts highlight that the higher price target reflects growing confidence in Sight Sciences' ability to monetize new Medicare coverage for its TearCare dry eye treatment system.내러티브 업데이트 • Dec 11
SGHT: Final Medicare Coverage Will Shape Dry Eye Outlook And Execution Risks
Analysts have modestly raised their price target on Sight Sciences from approximately $6.08 to about $7.85 per share, citing improved fair value estimates and expectations that finalized Medicare coverage for the TearCare dry eye treatment system could drive future outperformance. Analyst Commentary With the recent coverage decisions for TearCare by key Medicare administrative contractors, Street research has become more constructive on Sight Sciences' medium term outlook, though some execution risks remain in focus.내러티브 업데이트 • Nov 27
SGHT: Broader Medicare Coverage Will Increase Risks For Execution Going Forward
Analysts have raised their price target for Sight Sciences from $5.00 to $7.00 per share. They cite broader Medicare coverage for its Dry Eye Disease treatment system as a key factor supporting the positive outlook.분석 기사 • Nov 13
Sight Sciences (NASDAQ:SGHT) Has Debt But No Earnings; Should You Worry?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...내러티브 업데이트 • Nov 08
SGHT: Higher Medicare Access Will Increase Competitive Execution Risks Ahead
Analysts have raised their price target for Sight Sciences from approximately $4.42 to $5.08, citing expanded Medicare coverage and stronger growth expectations across key financial metrics. Analyst Commentary Bullish Takeaways Bullish analysts highlighted the substantial increase in the price target following newly finalized Medicare coverage for the TearCare system.분석 기사 • Oct 18
Market Participants Recognise Sight Sciences, Inc.'s (NASDAQ:SGHT) Revenues Pushing Shares 37% Higher
The Sight Sciences, Inc. ( NASDAQ:SGHT ) share price has done very well over the last month, posting an excellent gain...분석 기사 • Aug 09
Does Sight Sciences (NASDAQ:SGHT) Have A Healthy Balance Sheet?
NasdaqGS:SGHT 1 Year Share Price vs Fair Value Explore Sight Sciences's Fair Values from the Community and select yours...내러티브 업데이트 • Aug 08
Expanding Healthcare Access And Chronic Eye Disease Trends Will Boost Minimally Invasive Procedures
Sight Sciences' consensus price target has increased, primarily reflecting improved revenue growth forecasts, with fair value rising from $3.93 to $4.27. What's in the News Raised full-year 2025 revenue guidance to $72–76 million (still a 5–10% decline vs.분석 기사 • May 14
Sight Sciences, Inc. (NASDAQ:SGHT) Surges 44% Yet Its Low P/S Is No Reason For Excitement
Sight Sciences, Inc. ( NASDAQ:SGHT ) shareholders would be excited to see that the share price has had a great month...
새로운 내러티브 • Apr 04
OMNIEdge And TearCare Will Transform MIGS Treatments
Strategic initiatives, such as the OMNIEdge launch and positive reimbursement for TearCare, aim to capture market share and improve revenue and margins.분석 기사 • Mar 30
Sight Sciences, Inc. (NASDAQ:SGHT) Looks Inexpensive But Perhaps Not Attractive Enough
Sight Sciences, Inc.'s ( NASDAQ:SGHT ) price-to-sales (or "P/S") ratio of 1.6x might make it look like a buy right now...CEO 보수 분석
| 날짜 | 총 보수 | 급여 | 회사 수익 |
|---|---|---|---|
| Jun 30 2026 | n/a | n/a | -US$30m |
| Mar 31 2026 | n/a | n/a | -US$37m |
| Dec 31 2025 | US$2m | US$659k | -US$38m |
| Sep 30 2025 | n/a | n/a | -US$46m |
| Jun 30 2025 | n/a | n/a | -US$49m |
| Mar 31 2025 | n/a | n/a | -US$49m |
| Dec 31 2024 | US$3m | US$640k | -US$52m |
| Sep 30 2024 | n/a | n/a | -US$50m |
| Jun 30 2024 | n/a | n/a | -US$52m |
| Mar 31 2024 | n/a | n/a | -US$55m |
| Dec 31 2023 | US$4m | US$610k | -US$56m |
| Sep 30 2023 | n/a | n/a | -US$62m |
| Jun 30 2023 | n/a | n/a | -US$71m |
| Mar 31 2023 | n/a | n/a | -US$80m |
| Dec 31 2022 | US$6m | US$580k | -US$86m |
| Sep 30 2022 | n/a | n/a | -US$85m |
| Jun 30 2022 | n/a | n/a | -US$80m |
| Mar 31 2022 | n/a | n/a | -US$74m |
| Dec 31 2021 | US$9m | US$424k | -US$63m |
| Sep 30 2021 | n/a | n/a | -US$56m |
| Jun 30 2021 | n/a | n/a | -US$47m |
| Mar 31 2021 | n/a | n/a | -US$38m |
| Dec 31 2020 | US$497k | US$360k | -US$35m |
보상 대 시장: Paul의 총 보수(USD2.01M)는 US 시장에서 비슷한 규모 기업의 평균(USD2.41M) 수준입니다.
보상과 수익: Paul의 보상은 지난 1년 동안 회사 실적과 일치했습니다.
CEO
Paul Badawi (50 yo)
15.7yrs
재임 기간
US$2,005,608
보수
Mr. Paul Badawi is a Co-Founder of Sight Sciences, Inc. since 2011 and serves as its President and Chief Executive Officer since 2011. Mr. Badawi specializes in medical technology investments for 3i. His p...
리더십 팀
| 이름 | 직위 | 재임 기간 | 보수 | 지분 |
|---|---|---|---|---|
| Co-Founder | 15.7yrs | US$2.01m | 10.12% $ 45.4m | |
| Chief Operating Officer | less than a year | US$1.63m | 0.35% $ 1.6m | |
| Corporate Secretary | no data | US$974.25k | 0.18% $ 814.1k | |
| Co-Founder | 15.7yrs | 데이터 없음 | 3.29% $ 14.8m | |
| CFO & Treasurer | less than a year | 데이터 없음 | 0.10% $ 449.3k | |
| VP and Chief Ethics & Compliance Officer | 3.3yrs | 데이터 없음 | 데이터 없음 | |
| Chief Legal Officer | less than a year | 데이터 없음 | 데이터 없음 | |
| Vice President of Marketing & Commercial Strategy | less than a year | 데이터 없음 | 데이터 없음 | |
| Executive Vice President of Operations and R&D | 1.8yrs | 데이터 없음 | 0.067% $ 298.7k | |
| Senior Vice President of Market Access & Strategy | less than a year | 데이터 없음 | 데이터 없음 |
0.8yrs
평균 재임 기간
50yo
평균 나이
경험이 풍부한 관리: SGHT의 경영진은 경험이 부족한 것으로 간주됩니다(평균 재임 0.8 년) — 신규 팀일 수 있습니다.
이사회 구성원
| 이름 | 직위 | 재임 기간 | 보수 | 지분 |
|---|---|---|---|---|
| Co-Founder | 15.7yrs | US$2.01m | 10.12% $ 45.4m | |
| Co-Founder | 15.7yrs | 데이터 없음 | 3.29% $ 14.8m | |
| Independent Director | 1.4yrs | US$283.62k | 0.17% $ 772.8k | |
| Independent Director | 6.2yrs | US$202.50k | 0.30% $ 1.3m | |
| Independent Chairman | 8.9yrs | US$231.00k | 3.7% $ 16.6m | |
| Independent Director | 4.2yrs | US$189.61k | 0.15% $ 662.5k | |
| Independent Director | 3.3yrs | US$197.00k | 0.12% $ 557.1k |
6.2yrs
평균 재임 기간
61yo
평균 나이
경험이 풍부한 이사회: SGHT의 이사회는 경험이 있음으로 간주됩니다(평균 재임 6.2 년).
기업 분석 및 재무 데이터 상태
| 데이터 | 최종 업데이트 (UTC 시간) |
|---|---|
| 기업 분석 | 2026/09/14 18:04 |
| 종가 | 2026/09/14 00:00 |
| 수익 | 2026/06/30 |
| 연간 수익 | 2025/12/31 |
데이터 소스
당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.
| 패키지 | 데이터 | 기간 | 미국 소스 예시 * |
|---|---|---|---|
| 기업 재무제표 | 10년 |
| |
| 분석가 컨센서스 추정치 | +3년 |
|
|
| 시장 가격 | 30년 |
| |
| 지분 구조 | 10년 |
| |
| 경영진 | 10년 |
| |
| 주요 개발 | 10년 |
|
* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.
별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.
분석 모델 및 스노우플레이크
이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 GitHub 페이지에서 확인하실 수 있습니다. 또한 보고서 사용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.
Simply Wall St 분석 모델을 설계하고 구축한 에 대해 알아보세요.
산업 및 섹터 지표
산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.
분석가 소스
Sight Sciences, Inc.는 10명의 분석가가 다루고 있습니다. 이 중 7명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
| 분석가 | 기관 |
|---|---|
| Craig Bijou | BofA Global Research |
| Joanne Wuensch | Citigroup Inc |
| Frank Takkinen | Lake Street Capital Markets, LLC |